Children treated with gastric acid suppression therapy—particularly, proton pump inhibitors (PPIs)—had significantly higher healthcare- and community-associated Clostridium difficile infection.
Morbidly obese patients may require a lower mg/kg/day vancomycin dose than obese patients to reach the desired trough of >15-20mg/L.
Ceftolozane/tazobactam provides an empiric treatment option for infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
The antibiotic telavancin was generally well tolerated and had a safety profile similar to vancomycin in patients with cancer and bloodstream infections.
S-649266, a novel catechol-substituted siderophore cephalosporin for injection, showed potent in vitro activity against a broad spectrum of Gram-negative bacteria.
Mupirocin decreased the risk of Staphylococcus aureus infection among both dialysis and adult ICU patients in a meta-analysis of 37 studies.
Ceftazidime-avibactam demonstrated “potent activity” against contemporary Enterobacteriaceae (ENT) strains, including those producing prevalent CTX-M-variants.
Higher rates of acute kidney injury (AKI) occurred in hospitalized patients receiving a combination of piperacillin-tazobactam and vancomycin than in those receiving vancomycin alone, piperacillin-tazobactam alone, daptomycin and piperacillin-tazobactam, or vancomycin and doripenem.
Early life antibiotic exposure was not associated with increased childhood weight gain.
Eravacycline, a novel antibacterial agent, demonstrated high in vitro activity against Gram-negative pathogens, including multidrug-resistant isolates.
Please login or register first to view this content.
